ArticleScientific reports2025
Exploring the epidemiological characteristics of Mpox in the Arab Gulf countries.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
In May 2022, Mpox outbreaks emerged in regions where the virus is not traditionally prevalent. This study estimates the mean incubation period, serial interval and the extent of presymptomatic transmission in the Arab Gulf Countries (AGC). The effective reproduction number ([Formula: see text]) is also calculated, as well as the degree of heterogeneity ([Formula: see text]), using the instant-individual heterogeneity transmission model. We analyze data from 41 confirmed cases for which we have complete information, estimating the mean incubation period using gamma, Weibull and lognormal distributions, with respective means of 8.52 (95% CI 7.26-9.98), 8.57 (95% CI 7.28-10.01), and 8.64 (95% CI 7.23-10.26) days. The mean serial interval, based on 31 case pairs, was 7.19 days (95% CI 4.11-12.95), 7.16 days (95% CI 5.80-8.90), and 10.0 days (95% CI 6.30-16.3) for the gamma, Weibull, and lognormal distributions, respectively. The Akaike Information Criterion (AIC) validated the best-fitting models. The serial intervals were shorter than the incubation periods, suggesting that pre-symptomatic transmission occurred in 60% of transmission events. We estimated [Formula: see text] to be 0.95 (95% highest posterior density [HPD]: 0.93-1.35) and [Formula: see text] to be 1.52 (95% HPD: 1.07-5.76), indicating supercritical Mpox transmission in the AGC with limited transmission heterogeneity. Using a Bayesian framework with non-informative priors and a negative binomial distribution, we projected [Formula: see text] to remain between 0.95 and 1.0 from August 2022 to January 2023, underscoring the need for continued efforts to reduce transmissibility. These findings provide valuable information for public health interventions, emphasizing a multifaceted approach to managing Mpox transmission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.